Mesenchymal chondrosarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study on 57 patients

Background This study aimed to elucidate the clinical features and prognostic factors of mesenchymal chondrosarcoma (MCS) and investigate optimal treatment strategies. Methods Data from 57 patients with MCS were collected from a Japanese Musculoskeletal Oncology Group (JMOG) and retrospectively anal...

Full description

Saved in:
Bibliographic Details
Published in:Journal of surgical oncology 2017-05, Vol.115 (6), p.760-767
Main Authors: Tsuda, Yusuke, Ogura, Koichi, Hakozaki, Michiyuki, Kikuta, Kazutaka, Ae, Keisuke, Tsuchiya, Hiroyuki, Iwata, Shintaro, Ueda, Takafumi, Kawano, Hirotaka, Kawai, Akira
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bone cancer
Cancer surgery
Child
Chondrosarcoma, Mesenchymal - drug therapy
Chondrosarcoma, Mesenchymal - pathology
Chondrosarcoma, Mesenchymal - radiotherapy
Chondrosarcoma, Mesenchymal - therapy
clinical features
Female
Humans
Japan
Male
Medical prognosis
mesenchymal chondrosarcoma
Middle Aged
Prognosis
prognostic factors
Retrospective Studies
Surveys and Questionnaires
Treatment Outcome
Tumors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background This study aimed to elucidate the clinical features and prognostic factors of mesenchymal chondrosarcoma (MCS) and investigate optimal treatment strategies. Methods Data from 57 patients with MCS were collected from a Japanese Musculoskeletal Oncology Group (JMOG) and retrospectively analyzed. Results Data from 29 males and 28 females were collected. Primary tumor sites were the head and neck (7 patients), trunk (35 patients), and extremities (15 patients). The tumors originating in the trunk were significantly associated with a worse OS compared with those originating at the other sites in all patients and those with localized disease (P = 0.020 and P = 0.019, respectively). In patients with localized disease, the tumors originating in the head and neck were significantly associated with better OS and MFS compared with those originating in the trunk (P = 0.024 and P = 0.014, respectively). Positive surgical margin was significantly correlated with the worse LRFS (P = 0.018). Adjuvant chemotherapy exhibited a clear trend toward improved OS when MCS was localized in the trunk or extremities (P = 0.057). Conclusions Adequate surgery is considered to be the mainstay of treatment for localized MCS. Prognosis was different depending on the site of tumor origin.
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.24567